Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hyperplasia Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Compare 3 Different Formulations Of Tamsulosin At Steady State.

NCT00609596
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
GI198745
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Jul 23, 2026, 6:19 AM EDT
Terminated Phase 2 Interventional

Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer

NCT00003179
View directory record Official record
Conditions
Endometrial Cancer
Interventions
medroxyprogesterone
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
30
States / cities
Tucson, Arizona • Los Gatos, California • Orange, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2013 · Synced Jul 23, 2026, 6:19 AM EDT
Recruiting Not applicable Interventional

5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy

NCT04288427
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Prostate Hyperplasia, Prostate Disease, Prostate Hypertrophy, Prostate Pain, Lower Urinary Tract Symptoms, Urinary Obstruction, Urinary Tract Disease
Interventions
Finasteride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Jul 23, 2026, 6:19 AM EDT
Completed Phase 2 Interventional Results available

A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia

NCT02804178
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
ATR-101
Drug
Lead sponsor
Millendo Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Baltimore, Maryland • Bethesda, Maryland • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Jul 23, 2026, 6:19 AM EDT
Withdrawn No phase listed Observational

Protocol for Postmenopausal Women at Increased Risk of Developing Breast Cancer

NCT00329017
View directory record Official record
Conditions
Breast Cancer
Interventions
Fine needle aspiration
Procedure
Lead sponsor
Carol Fabian, MD
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Jul 23, 2026, 6:19 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of S-Equol on Men With Benign Prostatic Hyperplasia

NCT00962390
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
S-equol, Placebo
Drug
Lead sponsor
Ausio Pharmaceuticals, LLC
Industry
Eligibility
50 Years and older · Male only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
5
States / cities
Huntsville, Alabama • Aventura, Florida • Clearwater, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Jul 23, 2026, 6:19 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Prospective Evaluation of the GreenLight Model 120 Laser

NCT00364585
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
GreenLight Model 120 Laser System
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
40 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2008 · Synced Jul 23, 2026, 6:19 AM EDT
Terminated Not applicable Interventional

Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia Optimization Study

NCT04253418
View directory record Official record
Conditions
Sebaceous Hyperplasia, Skin Abnormalities, Skin Lesion
Interventions
Nano-Pulse Stimulation (NPS)
Device
Lead sponsor
Pulse Biosciences, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Scottsdale, Arizona • Sacramento, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Jul 23, 2026, 6:19 AM EDT
Terminated Phase 2 Interventional

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

NCT01194960
View directory record Official record
Conditions
Hormone Refractory Prostate Cancer
Interventions
Docetaxel, TroVax
Drug
Lead sponsor
Oxford BioMedica
Industry
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
7
States / cities
San Bernardino, California • Stanford, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Jul 23, 2026, 6:19 AM EDT
Active, not recruiting No phase listed Observational

Impact of COVID-19 on GU Disease

NCT04761107
View directory record Official record
Conditions
COVID-19 Infection, Genitourinary Cancer, Benign Urologic Conditions
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
40 Years and older
Enrollment
15,240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Jul 23, 2026, 6:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects

NCT02509104
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
FDC capsule of dutasteride and tamsulosin, Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Jul 23, 2026, 6:19 AM EDT
Active, not recruiting Not applicable Interventional

PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs

NCT06051942
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Localized Prostate Cancer
Interventions
Robotic Waterjet Treatment
Device
Lead sponsor
PROCEPT BioRobotics
Industry
Eligibility
Up to 80 Years · Male only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
La Mesa, California • Glenview, Illinois • Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jul 23, 2026, 6:19 AM EDT
Recruiting Not applicable Interventional

PRescription Exercise for Older Men With Urinary Disease

NCT06225479
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Interventions
Exercise, Calls and Newsletter
Behavioral · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
60 Years and older · Male only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Jul 23, 2026, 6:19 AM EDT
Completed Not applicable Interventional Results available

The Safety and Effectiveness of UroLift: LIFT Pivotal Study

NCT01294150
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
UroLift System, Cystoscopy, Crossover
Device · Other
Lead sponsor
NeoTract, Inc.
Industry
Eligibility
50 Years and older · Male only
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
14
States / cities
San Diego, California • San Jose, California • Englewood, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Jul 23, 2026, 6:19 AM EDT
Active, not recruiting Phase 2 Interventional

Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization

NCT04879940
View directory record Official record
Conditions
Prostate Carcinoma, Benign Prostatic Hyperplasia
Interventions
Merit Medical Embospheres, Radiation Therapy
Device · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
50 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 23, 2026, 6:19 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Emsella for Reducing tSUI After HOLEP

NCT07580404
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Enlarged Prostate With Lower Urinary Tract Symptoms, Enlarged Prostate (BPH)
Interventions
Emsella chair
Device
Lead sponsor
Northwestern University
Other
Eligibility
50 Years to 80 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 23, 2026, 6:19 AM EDT
Active, not recruiting Not applicable Interventional

Pelvic Floor Physical Therapy to Reduce Stress Urinary Incontinence After Holmium Laser Enucleation of the Prostate

NCT06209307
View directory record Official record
Conditions
Prostatic Hyperplasia, Stress Urinary Incontinence
Interventions
Pelvic floor physical therapy
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Jul 23, 2026, 6:19 AM EDT
Completed No phase listed Observational

Human Prostate Tissue Model to Maintain and Study Prostate Cancer Stem Cells

NCT02425800
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Prostate Carcinoma
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Jul 23, 2026, 6:19 AM EDT
Not listed Phase 4 Interventional

Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH)

NCT02021032
View directory record Official record
Conditions
Benign Prostate Hyperplasia
Interventions
Prolieve
Device
Lead sponsor
Medifocus, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
7
States / cities
Orlando, Florida • Roswell, Georgia • Shreveport, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Jul 23, 2026, 6:19 AM EDT
Completed Phase 1 Interventional

Optical Clearing of the Skin in Conjunction With Laser Treatments

NCT00580736
View directory record Official record
Conditions
Port Wine Stain, Nevus of Ota, Tattoos, Scars, Acne, Hypertrichosis, Sebaceous Gland Diseases
Interventions
Optical Clearing
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Jul 23, 2026, 6:19 AM EDT
Completed Phase 1Phase 2 Interventional

Dose Escalation Study With QLT0074 for Benign Prostatic Hyperplasia

NCT00077012
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
QLT0074, Photodynamic therapy
Drug
Lead sponsor
QLT Inc.
Industry
Eligibility
Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
5
States / cities
San Francisco, California • Washington D.C., District of Columbia • New Port Richey, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Jul 23, 2026, 6:19 AM EDT
Terminated No phase listed Observational

IIT-2022-Simultaneous Urolift™ and Median Lobe Enucleation

NCT06157164
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
UroLift™ System and Holmium Laser Enucleation of the Prostate (HoLEP)
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
45 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Jul 23, 2026, 6:19 AM EDT
Completed Phase 3 Interventional Results available

Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)

NCT00670306
View directory record Official record
Conditions
Benign Prostatic Hypertrophy
Interventions
Cetrorelix Pamoate
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
50 Years and older · Male only
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
56
States / cities
Homewood, Alabama • Huntsville, Alabama • Laguna Hills, California + 49 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2011 · Synced Jul 23, 2026, 6:19 AM EDT
Completed Phase 2 Interventional Results available

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

NCT01441063
View directory record Official record
Conditions
Castleman Disease, Multicentric Castleman Disease, Giant Lymph Node Hyperplasia
Interventions
Zidovudine, Tocilizumab, Valganciclovir (VGC)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Jul 23, 2026, 6:19 AM EDT